AIMS/HYPOTHESIS: Hepatic insulin resistance is thought to be a critical component in the pathogenesis of type 2 diabetes but the role of intrinsic insulin signalling pathways in the regulation of hepatic metabolism remains controversial. Global gene targeting in mice and in vitro studies have suggested that IRS2 mediates the physiological effects of insulin in the liver. Reduced hepatic production of IRS2 is found in many cases of insulin resistance. To investigate the role of IRS2 in regulating liver function in vivo, we generated mice that specifically lack Irs2 in the liver (LivIrs2KO). MATERIALS AND METHODS: Hepatic insulin signalling events were examined in LivIrs2KO mice by western blotting. Glucose homeostasis and insulin sensitivity were assessed by glucose tolerance tests and hyperinsulinaemic-euglycaemic clamp studies. The effects of high-fat feeding upon glucose homeostasis were also determined. Liver function tests were performed and expression of key metabolic genes in the liver was determined by RT-PCR. RESULTS: Proximal insulin signalling events and forkhead box O1 and A2 function were normal in the liver of LivIrs2KO mice, which displayed minimal abnormalities in glucose and lipid homeostasis, hepatic gene expression and liver function. In addition, hepatic lipid homeostasis and the metabolic response to a high-fat diet did not differ between LivIrs2KO and control mice. CONCLUSIONS/ INTERPRETATION: Our findings suggest that liver IRS2 signalling, surprisingly, is not required for the long-term maintenance of glucose and lipid homeostasis, and that extra-hepatic IRS2-dependent mechanisms are involved in the regulation of these processes.
AIMS/HYPOTHESIS: Hepatic insulin resistance is thought to be a critical component in the pathogenesis of type 2 diabetes but the role of intrinsic insulin signalling pathways in the regulation of hepatic metabolism remains controversial. Global gene targeting in mice and in vitro studies have suggested that IRS2 mediates the physiological effects of insulin in the liver. Reduced hepatic production of IRS2 is found in many cases of insulin resistance. To investigate the role of IRS2 in regulating liver function in vivo, we generated mice that specifically lack Irs2 in the liver (LivIrs2KO). MATERIALS AND METHODS:Hepatic insulin signalling events were examined in LivIrs2KO mice by western blotting. Glucose homeostasis and insulin sensitivity were assessed by glucose tolerance tests and hyperinsulinaemic-euglycaemic clamp studies. The effects of high-fat feeding upon glucose homeostasis were also determined. Liver function tests were performed and expression of key metabolic genes in the liver was determined by RT-PCR. RESULTS: Proximal insulin signalling events and forkhead box O1 and A2 function were normal in the liver of LivIrs2KO mice, which displayed minimal abnormalities in glucose and lipid homeostasis, hepatic gene expression and liver function. In addition, hepatic lipid homeostasis and the metabolic response to a high-fat diet did not differ between LivIrs2KO and control mice. CONCLUSIONS/ INTERPRETATION: Our findings suggest that liver IRS2 signalling, surprisingly, is not required for the long-term maintenance of glucose and lipid homeostasis, and that extra-hepatic IRS2-dependent mechanisms are involved in the regulation of these processes.
Authors: D J Withers; J S Gutierrez; H Towery; D J Burks; J M Ren; S Previs; Y Zhang; D Bernal; S Pons; G I Shulman; S Bonner-Weir; M F White Journal: Nature Date: 1998-02-26 Impact factor: 49.962
Authors: N Kubota; K Tobe; Y Terauchi; K Eto; T Yamauchi; R Suzuki; Y Tsubamoto; K Komeda; R Nakano; H Miki; S Satoh; H Sekihara; S Sciacchitano; M Lesniak; S Aizawa; R Nagai; S Kimura; Y Akanuma; S I Taylor; T Kadowaki Journal: Diabetes Date: 2000-11 Impact factor: 9.461
Authors: Agharul I Choudhury; Helen Heffron; Mark A Smith; Hind Al-Qassab; Allison W Xu; Colin Selman; Marcus Simmgen; Melanie Clements; Marc Claret; Gavin Maccoll; David C Bedford; Kazunari Hisadome; Ivan Diakonov; Vazira Moosajee; Jimmy D Bell; John R Speakman; Rachel L Batterham; Gregory S Barsh; Michael L J Ashford; Dominic J Withers Journal: J Clin Invest Date: 2005-03-24 Impact factor: 14.808
Authors: Marc Claret; Mark A Smith; Claude Knauf; Hind Al-Qassab; Angela Woods; Amanda Heslegrave; Kaisa Piipari; Julian J Emmanuel; André Colom; Philippe Valet; Patrice D Cani; Ghazala Begum; Anne White; Phillip Mucket; Marco Peters; Keiko Mizuno; Rachel L Batterham; K Peter Giese; Alan Ashworth; Remy Burcelin; Michael L Ashford; David Carling; Dominic J Withers Journal: Diabetes Date: 2011-01-24 Impact factor: 9.461
Authors: Agueda González-Rodríguez; Jose A Mas Gutierrez; Silvia Sanz-González; Manuel Ros; Deborah J Burks; Angela M Valverde Journal: Diabetes Date: 2009-12-22 Impact factor: 9.461
Authors: J Cantley; A I Choudhury; H Asare-Anane; C Selman; S Lingard; H Heffron; P Herrera; S J Persaud; D J Withers Journal: Diabetologia Date: 2007-03-29 Impact factor: 10.122
Authors: Samir Softic; Michelle Kirby; Nicholas G Berger; Noah F Shroyer; Stephen C Woods; Rohit Kohli Journal: PLoS One Date: 2012-06-20 Impact factor: 3.240
Authors: Stefania Carobbio; Rachel M Hagen; Christopher J Lelliott; Marc Slawik; Gema Medina-Gomez; Chong-Yew Tan; Audrey Sicard; Helen J Atherton; Nuria Barbarroja; Mikael Bjursell; Mohammad Bohlooly-Y; Sam Virtue; Antoinette Tuthill; Etienne Lefai; Martine Laville; Tingting Wu; Robert V Considine; Hubert Vidal; Dominique Langin; Matej Oresic; Francisco J Tinahones; Jose Manuel Fernandez-Real; Julian L Griffin; Jaswinder K Sethi; Miguel López; Antonio Vidal-Puig Journal: Diabetes Date: 2013-08-06 Impact factor: 9.461